OverviewSuggest Edit

Trevena Inc is a clinical stage biopharmaceutical company involved in the discovery and development of G-protein coupled receptors (GPCR) biased ligands. The Company's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena’s pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson’s disease.

TypePublic
Founded2008
HQBerwyn, PA, US
Websitetrevena.com

Latest Updates

Employees (est.) (Dec 2018)29(-43%)
Revenue (FY, 2020)$3.1 M(+9800%)
Share Price (Jun 2021)$2.1(+5%)
Cybersecurity ratingAMore

Key People/Management at Trevena

Barry Shin

Barry Shin

Senior Vice President, Chief Financial Officer
Scott Applebaum

Scott Applebaum

Chief Legal and Compliance Officer, SVP of Regulatory Affairs and Corporate Secretary
Mark A. Demitrack

Mark A. Demitrack

Senior Vice President, Chief Medical Officer
Joel S. Solomon

Joel S. Solomon

Vice President, Legal & Compliance
Michael S. Kramer

Michael S. Kramer

Vice President, Scientific Operations & Alliance Management
Katrine Sutton

Katrine Sutton

Vice President, Finance Planning & Analysis
Show more

Trevena Office Locations

Trevena has an office in Berwyn
Berwyn, PA, US (HQ)
955 Chesterbrook Blvd #110
Show all (1)

Trevena Financials and Metrics

Trevena Revenue

Trevena's revenue was reported to be $3.07 m in FY, 2020
USD

Revenue (Q1, 2021)

209.0k

Gross profit (Q1, 2021)

46.0k

Gross profit margin (Q1, 2021), %

22%

Net income (Q1, 2021)

(9.8m)

EBIT (Q1, 2021)

(10.0m)

Market capitalization (11-Jun-2021)

343.5m

Closing stock price (11-Jun-2021)

2.1

Cash (31-Mar-2021)

97.7m

EV

246.5m
Trevena's current market capitalization is $343.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.3m3.8m5.7m31.0k3.1m

Revenue growth, %

(40%)

Cost of goods sold

182.0k

Gross profit

2.9m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

625.0k1.9m1.9m1.9m1.9m3.0m209.0k

Cost of goods sold

163.0k

Gross profit

46.0k

Gross profit Margin, %

22%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

36.2m46.8m24.3m16.6m32.9m32.3m109.4m

Accounts Receivable

4.1m71.0k

Prepaid Expenses

1.4m607.0k1.7m570.0k

Inventories

669.2k1.9m1.8m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

91.3m81.6m72.2m29.1m43.7m39.0m34.5m36.8m25.2m18.7m14.0m18.1m18.1m24.0m24.3m20.3m23.8m29.3m28.1m54.8m112.7m97.7m

Accounts Receivable

296.0k

Prepaid Expenses

3.4m2.5m924.3k1.7m883.2k986.9k2.5m3.1m1.6m2.9m3.5m2.1m1.8m1.5m1.2m1.6m1.3m2.3m1.7m2.5m1.0m2.6m

Current Assets

94.7m84.2m73.1m102.5m107.3m170.0m166.0m147.6m121.3m100.8m87.7m78.7m63.4m67.3m71.2m61.6m55.3m47.0m29.8m57.2m113.7m109.6m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(49.7m)(50.5m)(103.0m)(71.9m)(30.8m)(24.9m)(29.4m)

Depreciation and Amortization

239.4k207.9k246.0k490.0k645.0k600.0k477.0k

Inventories

(2.9m)(2.8m)

Accounts Payable

4.2m2.8m7.1m(8.4m)(1.2m)(1.3m)3.4m
USDQ1, 2014

Financial Leverage

1.1 x
Show all financial metrics

Trevena Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Trevena Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Trevena Online and Social Media Presence

Embed Graph

Trevena News and Updates

Trevena to Present at the JMP Securities Life Sciences Conference

CHESTERBROOK, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive Of…

Block & Leviton LLP Announces a Notice of Pendency and Proposed Settlement of Class Action in the Tomaszewski v. Trevena, Inc., et al

BOSTON, June 7, 2021 /PRNewswire/ -- UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA DR. WILLIAM TOMASZEWSKI, Individually and on Behalf of All Others Similar Situated, Plaintiffs, v. TREVENA, INC., MAXINE GOWEN, and DAVID SOERGEL, Defendants. Civil Action No....

Trevena Announces Presentations of OLINVYK® Health Economic Models at ISPOR 2021

-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care

Trevena Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting

-- Elderly and obese patients receiving OLINVYK are not at increased risk for respiratory depression, compared to younger and non-obese patients, based on exploratory analysis

Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial

-- Vanderbilt University Medical Center (VUMC) is coordinating multiple-arm, multi-site ACTIV-4d study targeting RAAS

Trevena Reports First Quarter 2021 Results

-- Company reaffirms YE target of 100 formulary approvals for OLINVYK®
Show more

Trevena Blogs

Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum

CHESTERBROOK, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark A. Demitrack, M.D., Senior Vice President …

Trevena to Participate in Upcoming Conferences in September 2019

Trevena, Inc. today announced that its management team will participate in two upcoming conferences:

Trevena Advances NDA Resubmission Activities for Oliceridine

Trevena, Inc. today provided an update on the activities to support resubmission of the New Drug Application (NDA) for oliceridine.

Trevena Reports Second Quarter 2019 Results

Trevena, Inc. today reported its financial results for the second quarter ended June 30, 2019, and provided an overview of its recent operational highlights.

Trevena to Report Second Quarter 2019 Results on August 7, 2019

Trevena, Inc. today announced that it will release its financial results for the second quarter ended June 30, 2019 before the market opens on Wednesday, August 7, 2019.

Trevena Appoints Barry Shin as Chief Financial Officer

Trevena, Inc. today announced the appointment of Barry Shin as Chief Financial Officer. Mr. Shin comes to the Company with over 17 years of investment banking and corporate advisory experience, focused in the biopharmaceuticals sector.
Show more

Trevena Frequently Asked Questions

  • When was Trevena founded?

    Trevena was founded in 2008.

  • Who are Trevena key executives?

    Trevena's key executives are Barry Shin, Scott Applebaum and Mark A. Demitrack.

  • How many employees does Trevena have?

    Trevena has 29 employees.

  • What is Trevena revenue?

    Latest Trevena annual revenue is $3.1 m.

  • What is Trevena revenue per employee?

    Latest Trevena revenue per employee is $105.8 k.

  • Who are Trevena competitors?

    Competitors of Trevena include ADVANZ PHARMA, Recordati Rare Diseases and Tolmar.

  • Where is Trevena headquarters?

    Trevena headquarters is located at 955 Chesterbrook Blvd #110, Berwyn.

  • Where are Trevena offices?

    Trevena has an office in Berwyn.

  • How many offices does Trevena have?

    Trevena has 1 office.